About Tarak Mody

>28 years of business/corporate development, alliance management, intellectual property, and R&D Oncology experience in the biopharmaceutical industry.
Notable Highlights:
– $1.9 Billion Five Prime Therapeutics acquisition by Amgen, Inc. (April 16, 2021 close)
– ~$1.74 Billion global collaboration with Bristol Myers Squibb (anti-CSF1R antibody)
– ~$1 Billion global 50:50 global partnership with Janssen/J&J (ibrutinib/IMBRUVICA)
– Strategic Partnerships, licenses, with global and regional Pharma/biotech partners
– >100 issued US and international patents